Proteostasis Therapeutics, Inc. (NASDAQ:PTI) produced a 129.82% rally since recording the worst price of $1.71. Thanks to the latest 5.93% increase, it now trades at $3.93. Throughout the trading on 01/11/2019, the share price floated between $3.71 and $3.95. This company shares are 251.15% off its target price of $13.8 and the current market capitalization stands at $182.39M. The recent change has given its price a -22.68% deficit over SMA 50 and -62.14% deficit over its 52-week high. The stock witnessed -20.28% declines, 123.3% gains and 36.93% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PTI’s volatility during a week at 8.27% and during a month it has been found around 13.25%.Proteostasis Therapeutics, Inc. (PTI) Top Holders
Institutional investors currently hold around $91 million or 56.7% in PTI stock. Look at its top three institutional owners. Nea Management Company, Llc owns $21.84 million in Proteostasis Therapeutics, Inc., which represents roughly 11.97% of the company’s market cap and approximately 24% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 4,903,729 shares of the stock are valued at $19.27 million. The third largest holder is Jennison Associates Llc, which currently holds $14.5 million worth of this stock and that ownership represents nearly 7.95% of its market capitalization.Proteostasis Therapeutics, Inc. 13F Filings
At the end of September reporting period, 25 institutional holders increased their position in Proteostasis Therapeutics, Inc. (NASDAQ:PTI) by some 573,312 shares, 26 decreased positions by 1,106,102 and 15 held positions by 21,480,410. That puts total institutional holdings at 23,159,824 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 337,503 shares while 12 institutional investors sold out their entire positions totaling 675,602 shares.Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Insider Trades
Multiple company employees have indulged in significant insider trading. Proteostasis Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Berger Franklin M has acquired 40,000 shares of Proteostasis Therapeutics, Inc. (PTI) in trading session dated Oct. 26, 2018. These shares are worth $270,000 and were traded at $6.75 each. The SEC filing shows that Berger Franklin M performed a purchase of 60,000 shares. The Director added these shares by way of transaction on Dec. 18, 2017. The company’s shares were assimilated at $5 per share worth to an investment of some $300,000 on account of Berger Franklin M.
Director, Kelly Jeffery W., purchased 4,000 common shares of Proteostasis Therapeutics, Inc. (PTI) in the open market. In a transaction dated Dec. 18, 2017, the shares were bought at an average price of $5, giving away a sum of $20,000. After this purchase, 102,411 common shares of PTI are directly owned by the insider, with total stake valued at $402,475.
In the transaction dated Dec. 18, 2017, the great number of shares acquired came courtesy the President and CEO; Chhabra Meenu added a total of 40,000 shares at an average price of $5, amounting to approximately $200,000. The insider now directly owns 50,218 shares worth $197,357.Proteostasis Therapeutics, Inc. (PTI) Analyst Guide
Several analysts have released their opinion on Proteostasis Therapeutics, Inc. (NASDAQ:PTI), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.8 average brokerage recommendation.